We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

This study is currently recruiting participants.
Verified October 2017 by Therapeutics, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03307577
First Posted: October 11, 2017
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Therapeutics, Inc.
  Purpose
UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its vehicle cream in subjects with facial acne vulgaris.

Condition Intervention Phase
Acne Vulgaris Drug: UHE-101 Cream Other: Vehicle Cream Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
This is a double-blind study, which means that neither the patient nor the investigator will know which cream the patient is using.
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of UHE-101 Cream 1% When Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Resource links provided by NLM:


Further study details as provided by Therapeutics, Inc.:

Primary Outcome Measures:
  • Investigator's Global Assessment (IGA) "Success" [ Time Frame: Week 12 ]
    Proportion of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of "clear" or "almost clear" (IGA Score of 0 or 1) and a two or more grade improvement from Baseline.

  • Acne Lesion Counts (Absolute Change) [ Time Frame: Week 12 ]
    Absolute change from Baseline in Acne Lesion Counts in each treatment group at Week 12.


Secondary Outcome Measures:
  • IGA "Success" [ Time Frame: Week 4 ]
    Proportion of subjects achieving success in each treatment group at Week 4.

  • IGA "Success" [ Time Frame: Week 8 ]
    Proportion of subjects achieving success in each treatment group at Week 8.

  • Acne Lesion Counts (Absolute Change) [ Time Frame: Week 4 ]
    Absolute change from Baseline in Acne Lesion Counts in each treatment group at Week 4.

  • Acne Lesion Counts (Absolute Change) [ Time Frame: Week 8 ]
    Absolute change from Baseline in Acne Lesion Counts in each treatment group at Week 8.

  • Acne Lesion Counts (Percent Change) [ Time Frame: Week 4 ]
    Percent change from Baseline in lesion counts in each treatment group at Week 4

  • Acne Lesion Counts (Percent Change) [ Time Frame: Week 8 ]
    Percent change from Baseline in lesion counts in each treatment group at Week 8

  • Acne Lesion Counts (Percent Change) [ Time Frame: Week 12 ]
    Percent change from Baseline in lesion counts in each treatment group at Week 12


Estimated Enrollment: 48
Actual Study Start Date: October 5, 2017
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: UHE-101 cream, 1%
Cream is applied twice a day
Drug: UHE-101 Cream
Topical cream containing investigational drug at a concentration of 1%
Placebo Comparator: Vehicle cream
Cream is applied twice a day
Other: Vehicle Cream
Topical cream containing no drug (i.e., placebo)

Detailed Description:

The purpose of this study is to test a topical cream (UHE-101) containing 1.0% of active drug, for 12 weeks, in boys and girls, men and women, in the treatment of facial acne.

Patients who qualify for this study will apply the study cream twice daily (once in the morning and once in the evening) for 12 weeks.

Half of the patients in this study will receive UHE-101 cream and half will receive a vehicle cream that does not include an active drug (i.e., placebo). This is a double-blind study, which means that neither the patient nor the investigator will know which cream the patient is using. The study will last about 12 weeks and will involve 5 clinic visits.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient must provide written informed consent/assent. A patient under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the patient. If a patient becomes 18 years of age during the study, the patient must provide written informed consent at that time to continue study participation.
  2. Females must be post-menopausal, surgically sterile, or use an effective method of birth control.
  3. Patient has moderate to severe facial acne vulgaris.
  4. Patient must be in good general health as determined by the investigator and supported by medical history, physical and Vital Signs exam.

Exclusion Criteria:

  1. Females who are pregnant, lactating, or are planning to become pregnant during the study.
  2. Patient has active nodulocystic acne or acne conglobate, acne fulminans, or other forms of acne (e.g., acne mechanica).
  3. Patient has any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy.
  4. Patient has used any of the following topical anti-acne preparations or procedures on the face:

    • Topical anti-acne treatments including, but not limited to, over the-counter (OTC) acne cleansers or treatments, benzoyl peroxide, antibiotics, azelaic acid, dapsone, sulfa based products, corticosteroids, and salicylic acid within two weeks of Baseline;
    • Topical retinoids (e.g., tazarotene, adapalene, and tretinoin) within four weeks of Baseline;
    • Light treatments, microdermabrasion, or chemical peels within eight weeks of Baseline;
    • Other topical therapy, which may materially affect the patient's acne, in the investigator's opinion.
  5. Patient has used any of the following systemic anti-acne medications:

    • Corticosteroids (including intramuscular and intralesional injections) within four weeks of Baseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable;
    • Antibiotics or other systemic anti-acne medications within four weeks of Baseline, with the exception of five days or less of antibiotic therapy during this period, but not within one week of Baseline;
    • Androgen receptor blockers (i.e., spironolactone or flutamide) within eight weeks of Baseline; with the exception of five days or less of spironolactone therapy during this period, but not within one week of Baseline;
    • Retinoid therapy (e.g., isotretinoin) within six months of Baseline;
    • Vitamin A supplements (greater than 10,000 units per day) within six months of Baseline;
    • Other systemic therapy, which may materially affect the patient's acne, in the investigator's opinion.
  6. Patient has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
  7. Patient has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article or is currently enrolled in an investigational drug, device, or biologic study.
  8. Patient has a history of sensitivity to any of the ingredients in the test articles.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03307577


Contacts
Contact: Jim Berg 858-571-1800 projectmanager@therapeuticsinc.com

Locations
United States, California
Site 02 Recruiting
San Diego, California, United States, 92123
Contact    858-571-6800      
Sponsors and Collaborators
Therapeutics, Inc.
  More Information

Responsible Party: Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03307577     History of Changes
Other Study ID Numbers: 000-8651-202
First Submitted: October 5, 2017
First Posted: October 11, 2017
Last Update Posted: October 12, 2017
Last Verified: October 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases